FIELD: medicine.
SUBSTANCE: what is described is a composition for topical application which contains a continuous phase and at least one disperse phase with said composition containing at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue.
EFFECT: composition is characterised by better skin penetration or better stability.
27 cl, 3 dwg, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMIC COMPOSITION | 2012 |
|
RU2639472C2 |
| COMPOSITION FOR TOPICAL USE | 2019 |
|
RU2806765C2 |
| NOVEL COMPOSITIONS OF VACCINES | 2006 |
|
RU2422155C2 |
| PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2238734C2 |
| BIODEGRADABLE PLASTER | 2008 |
|
RU2460519C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING VITAMIN D AND CORTICOSTEROID | 2007 |
|
RU2452488C2 |
| PHARMACEUTICAL AEROSOL FORMULATION CONTAINING VITAMIN D ANALOGUE AND CORTICOSTEROID | 2011 |
|
RU2576607C2 |
| COMPOSITION CONTAINING LIPID NANOPARTICLES AND CORTICOSTEROID OR VITAMIN D DERIVATIVE | 2012 |
|
RU2602171C2 |
| COMPOSITION FOR TOPICAL USE | 2018 |
|
RU2807884C2 |
| COMPOSITIONS FOR TOPICAL USING COMPRISING AT LEAST ONE VITAMIN D OR ONE VITAMIN D ANALOG AND AT LEAST ONE CORTICOSTEROID | 2001 |
|
RU2271810C2 |
